NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $53.59 -2.61 (-4.64%) Closing price 10/1/2026 04:00 PM EasternExtended Trading$53.63 +0.04 (+0.08%) As of 10/1/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AtriCure Stock (NASDAQ:ATRC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AtriCure alerts:Sign Up Key Stats Today's Range$52.60▼$56.9950-Day Range$35.04▼$60.7752-Week Range$25.36▼$61.70Volume1.97 million shsAverage Volume1.53 million shsMarket Capitalization$2.73 billionP/E Ratio255.20Dividend YieldN/APrice Target$53.30Consensus RatingModerate Buy Company Overview AtriCure, Inc. is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart. The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF. AtriCure also offers the EPi-Sense system, which is used in hybrid and minimally invasive procedures for AF treatment, as well as technologies designed to support the management of post-operative pain. Founded in 2000, AtriCure is headquartered in Mason, Ohio. The company serves hospitals, cardiac surgeons, electrophysiologists and other healthcare providers in the United States and international markets through direct operations and distribution relationships. Its products are intended to support open, minimally invasive and hybrid approaches to cardiac care.AI Generated. May Contain Errors. Read More AtriCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreATRC MarketRank™: AtriCure scored higher than 59% of companies evaluated by MarketBeat, and ranked 383rd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingAtriCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 7 buy ratings, 4 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for AtriCure is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAtriCure has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AtriCure's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth55.17% Earnings GrowthEarnings for AtriCure are expected to grow by 55.17% in the coming year, from $0.29 to $0.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is 255.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.52.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is 255.20, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.64.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 5.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AtriCure's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.76% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 3.62, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AtriCure has recently increased by 3.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.77 News SentimentAtriCure has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for AtriCure this week, compared to 4 articles on an average week.Search Interest4 people have searched for ATRC on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows4 people have added AtriCure to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,317,897.00 in company stock.Percentage Held by Insiders4.00% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATRC Stock News HeadlinesConfira a cotação ATRC hoje e acompanhe as ações AtriCure em tempo real.September 27, 2026 | br.investing.comAtriCure, Inc. (NASDAQ:ATRC) Stock Has Consensus Price Target of $53.30 According to BrokeragesSeptember 26, 2026 | americanbankingnews.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)AtriCure (ATRC) Stock Looks Rich Against Its Sales BaseSeptember 25, 2026 | finance.yahoo.comWhy AtriCure (ATRC) Is Back In The SpotlightSeptember 25, 2026 | finance.yahoo.comInsider Selling: AtriCure (NASDAQ:ATRC) Insider Sells 4,519 Shares of StockSeptember 25, 2026 | insidertrades.comAtriCure (NASDAQ:ATRC) Director Sells $288,070.86 in StockSeptember 15, 2026 | insidertrades.comAtriCure (NASDAQ:ATRC) Insider Salvatore Privitera Sells 7,763 Shares of StockSeptember 5, 2026 | insidertrades.comSee More Headlines ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $39.56 on January 1st, 2026. Since then, ATRC stock has increased by 35.5% and is now trading at $53.59. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings results on Thursday, July, 23rd. The medical device company reported $0.18 earnings per share for the quarter, beating analysts' consensus estimates of $0.00 by $0.18. The medical device company earned $153.60 million during the quarter, compared to analysts' expectations of $151.80 million. AtriCure had a net margin of 1.85% and a trailing twelve-month return on equity of 2.34%. Read the conference call transcript. Does AtriCure have any subsidiaries? The following companies are subsidiaries of AtriCure: SentreHEART. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD). Company Calendar Last Earnings7/23/2026Today10/02/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ATRC's financial health is in the Green zone, according to TradeSmith. ATRC has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:ATRC CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,350Year Founded2000Price Target and Rating Average Price Target for AtriCure$53.30 High Price Target$65.00 Low Price Target$36.00 Potential Upside/Downside-0.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$0.21 Trailing P/E Ratio255.20 Forward P/E Ratio184.79 P/E GrowthN/ANet Income-$11.45 million Net Margins1.85% Pretax Margin2.12% Return on Equity2.34% Return on Assets1.77% Debt Debt-to-Equity Ratio0.14 Current Ratio4.22 Quick Ratio3.19 Sales & Book Value Annual Sales$534.53 million Price / Sales5.10 Cash Flow$0.30 per share Price / Cash Flow179.56 Book Value$9.89 per share Price / Book5.42Miscellaneous Outstanding Shares50,870,000Free Float48,831,000Market Cap$2.73 billion OptionableOptionable Beta1.24 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ATRC) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersThey're not telling you how bad this could getValuations are stretched to levels seen only a handful of times in the past century, while a growing debt spir...Parkview Capital Group | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
